|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: STX6 |
Gene summary for STX6 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | STX6 | Gene ID | 10228 |
| Gene name | syntaxin 6 | |
| Gene Alias | STX6 | |
| Cytomap | 1q25.3 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | O43752 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10228 | STX6 | CA_HPV_3 | Human | Cervix | CC | 1.76e-03 | 4.34e-02 | 0.0414 |
| 10228 | STX6 | CCI_2 | Human | Cervix | CC | 2.37e-05 | 7.74e-01 | 0.5249 |
| 10228 | STX6 | CCI_3 | Human | Cervix | CC | 2.82e-03 | 5.25e-01 | 0.516 |
| 10228 | STX6 | sample3 | Human | Cervix | CC | 1.49e-02 | 1.36e-01 | 0.1387 |
| 10228 | STX6 | LZE4T | Human | Esophagus | ESCC | 3.57e-06 | 1.48e-01 | 0.0811 |
| 10228 | STX6 | LZE7T | Human | Esophagus | ESCC | 3.05e-14 | 5.69e-01 | 0.0667 |
| 10228 | STX6 | LZE20T | Human | Esophagus | ESCC | 8.82e-03 | 2.48e-01 | 0.0662 |
| 10228 | STX6 | LZE24T | Human | Esophagus | ESCC | 2.80e-12 | 2.14e-01 | 0.0596 |
| 10228 | STX6 | LZE6T | Human | Esophagus | ESCC | 4.90e-08 | 1.78e-01 | 0.0845 |
| 10228 | STX6 | P1T-E | Human | Esophagus | ESCC | 2.41e-14 | 4.82e-01 | 0.0875 |
| 10228 | STX6 | P2T-E | Human | Esophagus | ESCC | 3.48e-32 | 6.66e-01 | 0.1177 |
| 10228 | STX6 | P4T-E | Human | Esophagus | ESCC | 1.84e-26 | 6.78e-01 | 0.1323 |
| 10228 | STX6 | P5T-E | Human | Esophagus | ESCC | 5.38e-28 | 4.87e-01 | 0.1327 |
| 10228 | STX6 | P8T-E | Human | Esophagus | ESCC | 2.25e-17 | 2.39e-01 | 0.0889 |
| 10228 | STX6 | P9T-E | Human | Esophagus | ESCC | 4.44e-08 | 2.70e-01 | 0.1131 |
| 10228 | STX6 | P10T-E | Human | Esophagus | ESCC | 1.64e-20 | 3.96e-01 | 0.116 |
| 10228 | STX6 | P11T-E | Human | Esophagus | ESCC | 4.57e-13 | 6.44e-01 | 0.1426 |
| 10228 | STX6 | P12T-E | Human | Esophagus | ESCC | 6.30e-29 | 3.31e-01 | 0.1122 |
| 10228 | STX6 | P15T-E | Human | Esophagus | ESCC | 1.58e-18 | 5.09e-01 | 0.1149 |
| 10228 | STX6 | P16T-E | Human | Esophagus | ESCC | 5.15e-36 | 6.20e-01 | 0.1153 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:01400567 | Esophagus | ESCC | organelle localization by membrane tethering | 53/8552 | 77/18723 | 3.33e-05 | 2.74e-04 | 53 |
| GO:00610254 | Esophagus | ESCC | membrane fusion | 98/8552 | 163/18723 | 1.39e-04 | 9.41e-04 | 98 |
| GO:00482781 | Esophagus | ESCC | vesicle docking | 38/8552 | 59/18723 | 2.86e-03 | 1.21e-02 | 38 |
| GO:00901614 | Esophagus | ESCC | Golgi ribbon formation | 11/8552 | 13/18723 | 4.76e-03 | 1.85e-02 | 11 |
| GO:00995324 | Esophagus | ESCC | synaptic vesicle endosomal processing | 9/8552 | 10/18723 | 5.09e-03 | 1.92e-02 | 9 |
| GO:00481936 | Liver | NAFLD | Golgi vesicle transport | 66/1882 | 296/18723 | 3.66e-10 | 9.30e-08 | 66 |
| GO:0007030 | Liver | NAFLD | Golgi organization | 36/1882 | 157/18723 | 1.76e-06 | 7.68e-05 | 36 |
| GO:00988765 | Liver | NAFLD | vesicle-mediated transport to the plasma membrane | 30/1882 | 136/18723 | 2.76e-05 | 7.39e-04 | 30 |
| GO:00164825 | Liver | NAFLD | cytosolic transport | 34/1882 | 168/18723 | 5.52e-05 | 1.25e-03 | 34 |
| GO:00161975 | Liver | NAFLD | endosomal transport | 41/1882 | 230/18723 | 2.02e-04 | 3.53e-03 | 41 |
| GO:00160505 | Liver | NAFLD | vesicle organization | 50/1882 | 300/18723 | 2.42e-04 | 4.06e-03 | 50 |
| GO:0090161 | Liver | NAFLD | Golgi ribbon formation | 6/1882 | 13/18723 | 9.41e-04 | 1.12e-02 | 6 |
| GO:00421474 | Liver | NAFLD | retrograde transport, endosome to Golgi | 19/1882 | 91/18723 | 1.55e-03 | 1.67e-02 | 19 |
| GO:00995321 | Liver | NAFLD | synaptic vesicle endosomal processing | 5/1882 | 10/18723 | 1.67e-03 | 1.74e-02 | 5 |
| GO:004819321 | Liver | HCC | Golgi vesicle transport | 217/7958 | 296/18723 | 2.58e-27 | 1.02e-24 | 217 |
| GO:001605021 | Liver | HCC | vesicle organization | 194/7958 | 300/18723 | 5.58e-15 | 3.97e-13 | 194 |
| GO:001619721 | Liver | HCC | endosomal transport | 154/7958 | 230/18723 | 4.74e-14 | 2.95e-12 | 154 |
| GO:001648221 | Liver | HCC | cytosolic transport | 117/7958 | 168/18723 | 8.83e-13 | 4.48e-11 | 117 |
| GO:009887621 | Liver | HCC | vesicle-mediated transport to the plasma membrane | 92/7958 | 136/18723 | 2.57e-09 | 7.07e-08 | 92 |
| GO:000703211 | Liver | HCC | endosome organization | 61/7958 | 82/18723 | 4.36e-09 | 1.15e-07 | 61 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa041305 | Esophagus | ESCC | SNARE interactions in vesicular transport | 28/4205 | 33/8465 | 2.75e-05 | 1.32e-04 | 6.75e-05 | 28 |
| hsa0413012 | Esophagus | ESCC | SNARE interactions in vesicular transport | 28/4205 | 33/8465 | 2.75e-05 | 1.32e-04 | 6.75e-05 | 28 |
| hsa041302 | Liver | HCC | SNARE interactions in vesicular transport | 25/4020 | 33/8465 | 8.78e-04 | 3.38e-03 | 1.88e-03 | 25 |
| hsa041303 | Liver | HCC | SNARE interactions in vesicular transport | 25/4020 | 33/8465 | 8.78e-04 | 3.38e-03 | 1.88e-03 | 25 |
| hsa041304 | Oral cavity | OSCC | SNARE interactions in vesicular transport | 28/3704 | 33/8465 | 1.31e-06 | 7.18e-06 | 3.66e-06 | 28 |
| hsa0413011 | Oral cavity | OSCC | SNARE interactions in vesicular transport | 28/3704 | 33/8465 | 1.31e-06 | 7.18e-06 | 3.66e-06 | 28 |
| hsa0413021 | Oral cavity | LP | SNARE interactions in vesicular transport | 22/2418 | 33/8465 | 6.00e-06 | 4.76e-05 | 3.07e-05 | 22 |
| hsa0413031 | Oral cavity | LP | SNARE interactions in vesicular transport | 22/2418 | 33/8465 | 6.00e-06 | 4.76e-05 | 3.07e-05 | 22 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| STX6 | SNV | Missense_Mutation | novel | c.583G>A | p.Glu195Lys | p.E195K | O43752 | protein_coding | deleterious(0) | benign(0.3) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| STX6 | SNV | Missense_Mutation | c.214G>A | p.Glu72Lys | p.E72K | O43752 | protein_coding | deleterious(0.01) | possibly_damaging(0.865) | TCGA-EW-A1PE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD | |
| STX6 | insertion | Nonsense_Mutation | novel | c.456_457insATGTTCTTTTGTTCTTTACATTAGTATGTCTGCTTAACCAG | p.His153MetfsTer8 | p.H153Mfs*8 | O43752 | protein_coding | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| STX6 | SNV | Missense_Mutation | c.204N>G | p.Ile68Met | p.I68M | O43752 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-C5-A1M5-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
| STX6 | SNV | Missense_Mutation | c.250G>A | p.Glu84Lys | p.E84K | O43752 | protein_coding | deleterious(0.01) | probably_damaging(0.993) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| STX6 | SNV | Missense_Mutation | rs776504795 | c.206G>A | p.Ser69Asn | p.S69N | O43752 | protein_coding | tolerated(0.7) | benign(0) | TCGA-A6-3807-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Ancillary | leucovorin | SD |
| STX6 | SNV | Missense_Mutation | c.343G>A | p.Ala115Thr | p.A115T | O43752 | protein_coding | tolerated(0.59) | benign(0.001) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| STX6 | SNV | Missense_Mutation | novel | c.380N>A | p.Ser127Asn | p.S127N | O43752 | protein_coding | tolerated(0.15) | benign(0.009) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| STX6 | SNV | Missense_Mutation | novel | c.112N>T | p.Ala38Ser | p.A38S | O43752 | protein_coding | tolerated(0.32) | benign(0.03) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| STX6 | SNV | Missense_Mutation | c.448G>A | p.Ala150Thr | p.A150T | O43752 | protein_coding | tolerated(0.15) | benign(0.027) | TCGA-D1-A177-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |